Regenxbio Inc expected to post a loss of $1.15 a share - Earnings Preview

Regenxbio

11/03/2025 20:38

Regenxbio Inc RGNX.OQ RGNX.O is expected to show a rise in quarterly revenue when it reports  results on March 13 for the period ending December 31 2024

The Rockville Maryland-based  company is expected to report a 6.9% increase in revenue to $23.754 million from $22.21 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

‚ÄãLSEG's mean analyst estimate for Regenxbio Inc is for a loss of $1.15 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äã

Wall Street's median 12-month price target for Regenxbio Inc is $28.50‚Äã, above‚Äã its last closing price of $6.01. ‚Äã‚Äã‚Äã

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äã

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-1.11
-1.12
-1.17
Missed
-4.3
Jun. 30 2024
-1.30
-1.29
-1.05
Beat
18.7
Mar. 31 2024
-1.29
-1.26
-1.33
Missed
-5.6‚Äã
Dec. 31 2023
-1.30
-1.27
-1.43
Missed
-12.5
‚Äã‚ÄãSep. 30 2023
-1.56
-1.52
-1.41
Beat
7.1
Jun. 30 2023
-1.43
-1.38
-1.66
Missed
-19.9‚Äã
Mar. 31 2023
-1.60
-1.54
-1.53
Beat
0.4
Dec. 31 2022
-1.24
-1.23
-1.38
Missed
-11.8

This summary was machine generated March 11 at 20:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)